Affiliation:
1. Department of Health Sciences, Cape Breton University, Sydney, Nova Scotia, Canada
Abstract
Introduction:
Type 2 Diabetes (T2D) cases continue to rise dramatically despite efforts to
get people to exercise and eat with a view to health and combatting the cluster of 7 issues (central obesity
(elevated waist circumference), hyperglycaemia, hypertension, dyslipidemia, pro-thrombotic state,
increased oxidation (including Low-density Lipoprotein (LDL)) and the pro-inflammatory state associated
with pre- and post-onset T2D.
Background:
There are numerous medications available to deal with these seven major issues. However,
each medication currently available manages a maximum of two cluster members at a time. Consequently,
polypharmacy is frequently required to manage the cluster of seven. Polypharmacy brings
with it high financial costs for numerous medications, the risk of poor compliance (particularly so in
older patients), side effects and drug interactions. Thus, there is a search for new agents that reduce the
high costs and risks of polypharmacy while at the same time combatting three or more of the cluster of
seven. There is very limited evidence to suggest that one or more lignans may efficaciously and safely,
in the short and long term, manage at least three of the cluster of seven, pre- and post-T2D onset, thus
reducing polypharmacy. However, multi-centre, large clinical trials are required before any definitive
conclusions about these lignans can be reached regarding their safe and efficacious polypharmacy
reduction potential, both long and short-term, in pre and post-onset T2D management.
Conclusion:
It is concluded that some lignans appear to have the potential to manage at least three
members of the cluster of seven in pre- or post-T2D onset and hence reduce polypharmacy but much
more investigation is required to confirm if such is the case. At the moment, there is not enough evidence
that any of the lignans will, in the long or short term, safely and efficaciously manage the cluster
of seven via polypharmacy reduction.
Publisher
Bentham Science Publishers Ltd.
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献